Spyre Therapeutics (SYRE) Accumulated Expenses (2016 - 2025)
Historic Accumulated Expenses for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to $23.8 million.
- Spyre Therapeutics' Accumulated Expenses rose 8115.26% to $23.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.8 million, marking a year-over-year increase of 8115.26%. This contributed to the annual value of $27.7 million for FY2024, which is 11140.52% up from last year.
- Spyre Therapeutics' Accumulated Expenses amounted to $23.8 million in Q3 2025, which was up 8115.26% from $19.4 million recorded in Q2 2025.
- In the past 5 years, Spyre Therapeutics' Accumulated Expenses registered a high of $28.4 million during Q2 2023, and its lowest value of $5.7 million during Q2 2024.
- In the last 5 years, Spyre Therapeutics' Accumulated Expenses had a median value of $13.2 million in 2024 and averaged $15.8 million.
- Its Accumulated Expenses has fluctuated over the past 5 years, first crashed by 8000.84% in 2024, then soared by 24165.05% in 2025.
- Over the past 5 years, Spyre Therapeutics' Accumulated Expenses (Quarter) stood at $14.0 million in 2021, then decreased by 8.5% to $12.8 million in 2022, then grew by 2.11% to $13.1 million in 2023, then soared by 111.41% to $27.7 million in 2024, then dropped by 14.02% to $23.8 million in 2025.
- Its last three reported values are $23.8 million in Q3 2025, $19.4 million for Q2 2025, and $21.6 million during Q1 2025.